Gongwin Biopharm Holdings Co., Ltd. (TPEX:6617)

Gongwin Biopharm Holdings Revenue

Gongwin Biopharm Holdings had revenue of 11.77M TWD in the quarter ending September 30, 2026, a decrease of -3.22%. This brings the company's total for the last twelve months to 41.83M, up 11.66% year-over-year. In the year 2025, Gongwin Biopharm Holdings had annual revenue of 36.45M with 13.75% growth. That makes Gongwin Biopharm Holdings the 43,248th largest company in the world by revenue and 2,157th in Taiwan.

• Revenue (ttm): 41.83M
• Revenue Growth: +11.66%
• P/S Ratio: 396.67
• Revenue / Employee: n/a
• Employees: n/a
• Market Cap: 16.59B

Revenue Chart

Chart

Chart

Revenue by Geography

Chart

• Hong Kong and Mainland China 35.07M 96.2%
• Taiwan 1.38M 3.8%

Fiscal year ended Dec 31, 2025 See the full Gongwin Biopharm Holdings breakdown

Revenue History

Fiscal Year End	Revenue	Change	Growth
Dec 31, 2025	36.45M	4.41M	13.75%
Dec 31, 2024	32.04M	13.13M	69.39%
Dec 31, 2023	18.92M	17.77M	1,554.86%
Dec 31, 2022	1.14M	-	-
Dec 31, 2021	1.14M	310.00K	37.21%

Data Source: S&P Global Market Intelligence Last updated: Nov 9, 2026

Revenue data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Nov 14, 2026

Data Sources Report a data error